This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytokinetics: Pump Up the Volume

Editor's note: Adam Feuerstein will be the featured guest on TSC Live at noon EDT Tuesday, Sept. 29. Send him your questions by: Emailing us at; posting them on our Facebook page,; Tweeting us @thestreet_news with #tsclive; or posting them on the live show page in the comments section. Bookmark the TSC Live page now.

SAN FRANCISCO ( TheStreet) -- Cytokinetics (CYTK - Get Report) traded sharply higher during Friday's session with gains coming on heavy volume following rumors of a possible acquisition by Amgen (AMGN - Get Report).

Cytokinetics saw 2.5 million shares change hands Friday, many times greater than the 50-day average daily volume of 418,000 shares, after reported market chatter of a possible deal that would see Amgen acquire the small-cap biotech company.

Volume was greatest during the 2 p.m. EDT hour, when Cytokinetics' stock hit an intraday high of $5.20, close to its 52-week high. Shares were lately up 55 cents, or 12.3%, at $5.03.

Cytokinetics has a 45.3 million-share float with a small short interest float of 2.2% as of Aug. 26, according to Yahoo! Finance. Amgen, on the other hand, has a float of one billion and a short interest float of 2.2%. Amgen has a market cap of $61.5 billion, compared to Cytokinetics' $303 million market cap.

Cytokinetics shares are poised to finish the week with an advance of more than 25%. On Monday, the stock popped after a Wedbush Morgan analyst increased the firm's price target to $18 from $4, citing the company's focus on drugs that improve muscle function.

Investor posts on Internet message boards Friday argued that Cytokinetics is undervalued, given the company's potential when compared to other biotech companies. Others noted that rumors of a partnership with Amgen first popped up a few months earlier. Some traders pointed out that the stock is now only back to trading where it was a year ago.

-- Written by Robert Holmes in New York.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $158.30 0.00%
CYTK $8.14 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs